SCHEMBL4608574

SCHEMBL4608574

Nc1ccc(C(=O)c2ccccc2)cc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.58
ATM Q13315 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 1/20 0.54
MEN1 O00255 2/20 0.53
RAB9A P51151 2/20 0.53
KMT2A Q03164 2/20 0.53
NPC1 O15118 2/20 0.53
SRD5A2 P31213 1/20 0.52
MAPT P10636 3/20 0.51
POLB P06746 1/20 0.51
CNR2 P34972 2/20 0.51
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
CNR1 P21554 1/20 0.49
MAPK13 O15264 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9114963 0.90 L3MBTL1 (0.54) PBRM1ATMTDP1L3MBTL1MAPK1
SCHEMBL29412590 0.90 HSD17B10 (0.52) PBRM1L3MBTL1MAPK1ALDH1A1MEN1
SCHEMBL766129 0.90 HSD17B10 (0.52) PBRM1L3MBTL1MAPK1ALDH1A1MEN1
SCHEMBL9328747 0.89 SRD5A2 (0.58) TDP1L3MBTL1SRD5A2MAPTPOLB
SCHEMBL11133333 0.85 MAPK1 (0.58) PBRM1ATMTDP1L3MBTL1MAPK1
Benzophenone SCHEMBL27781305 0.84 PBRM1 (0.62) PBRM1ATMTDP1L3MBTL1MAPK1
SCHEMBL30874183 0.84 PBRM1 (0.62) PBRM1ATMTDP1L3MBTL1MAPK1
SCHEMBL144914 0.84 PBRM1 (0.62) PBRM1ATMTDP1L3MBTL1MAPK1
SCHEMBL6853626 0.82 GAA (0.47) L3MBTL1MAPK1ALDH1A1MEN1RAB9A
SCHEMBL31257839 0.82 L3MBTL1 (0.64) PBRM1ATMTDP1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1059927-B1 CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 2008-07-30 EP disclosed
EP-0809492-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2007-01-24 EP disclosed
CN-1539816-A IL-8 receptor antagonists ʷ��˿�������ȳ�ķ���޹�˾ 2004-10-27 CN disclosed
EP-1185261-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-02-25 EP disclosed
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
CN-1355697-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 2002-06-26 CN disclosed
US-6369273-B1 ARYL ALCOHOLS OR ESTERS FOR ELEVATION OF PYRUVATE DHYDROGENASE ASTRAZENECA AB (SE) 2002-04-09 US disclosed
EP-1185261-A1 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-13 EP disclosed
EP-0617010-B1 Therapeutic compounds ASTRAZENECA AB (SE) 2002-01-09 EP disclosed
US-5886044-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-03-23 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
EP-0809492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed
WO-1996025157-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-08-22 WO disclosed
US-5482969-A Certain N(4-benzoyl-2-phenyl)-3- trifluoro-2-hydroxy-propanamide derivatives ZENECA LIMITED (GB) 1996-01-09 US disclosed
EP-0649402-A1 PRO-DRUG CAPABLE OF RELEASING AN OXAZOLIDINONE AND, IF NEED BE, AN ACETAMIDOPHENOL UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) 1995-04-26 EP disclosed
EP-0617010-A1 Therapeutic compounds ZENECA LIMITED (GB) 1994-09-28 EP disclosed
WO-1994001395-A1 PRO-DRUG CAPABLE OF RELEASING AN OXAZOLIDINONE AND, IF NEED BE, AN ACETAMIDOPHENOL UNIVERSITE PAUL SABATIER TOULOUSE III (FR) 1994-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN PBRM1 1806/4885ATM 3914/4885TDP1 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.